Long-term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Marcus Maurer*, Emel Aygören-Pürsün, Laurence Bouillet, Hugo Chapdelaine, Henriette Farkas, Delphine Gobert, Roman Hakl, Ramon Lleonart, Avner Reshef, Giuseppe Spadaro, Maria Staevska, Marcin Stobiecki, Justin Sun, Li Zhu, Ming Yu, Giorgio Giannattasio, Peng Lu, **Anna Valerieva**

ACARE Global Angioedema Forum 2024
Copenhagen, Denmark; 4 – 5 October 2024

This presentation includes data for an investigational product not yet approved by regulatory authorities.

***Our distinguished colleague and friend, Prof. Marcus Maurer, sadly passed away during the finalization of this slide presentation.**

Conflicts of interest disclosure

Grants/research support, honoraria or consultation fees, sponsored speaker bureau

M.M.: Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, Takeda; **A.V.:** AstraZeneca, Berlin-Chemie/Menarini Group, CSL Behring, KalVista, Novartis, Pharming, Pharvaris, Sobi, Takeda; **L.B.:** BioCryst, Blueprint, CSL Behring, Novartis, Takeda; **H.C.:** AstraZeneca (Alexion), CSL Behring, KalVista, Merck, Novartis, Pharming, Pharvaris, Roche, Sanofi, Sobi, Takeda; **H.F.:** BioCryst, CSL Behring, Intellia, KalVista, ONO Pharmaceutical, Pharming, Pharvaris, Takeda; **D.G.:** Pharming, Takeda; **R.H.:** BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, Takeda; **R.L.:** BioCryst, CSL Behring, Ionis, KalVista, Novartis, Pharming, Pharvaris, Takeda; **A.R.:** BioCryst, CSL Behring, Pharming, Pharvaris, Stallergens, Takeda, Teva; **G.S.:** Pharvaris, Takeda; **M.Sta.:** none; **M.Sto.:** BioCryst, CSL Behring, KalVista, Pharming, Takeda; **J.S., L.Z., M.Y., G.G.:** employees of Pharvaris, hold stocks in Pharvaris; **P.L.:** employee of Pharvaris, holds stocks/stock options in Pharvaris; **E.A.-P.:** Astria, BioCryst, BioMarin, CSL Behring, Intellia, KalVista, Pharming, Pharvaris, Takeda.

RAPIDe-2 is a Pharvaris-sponsored clinical trial. ClinicalTrials.gov identifier: NCT05396105.

Acknowledgments: Medical writing services were provided by Scott Salsman, Ph.D. of Two Labs Pharma Services.

Hereditary angioedema (HAE) is a bradykinin-mediated condition with unmet medical needs



- International guidelines recommend that HAE attacks are **treated as early as possible**[1-3]
- Burden associated with **parenteral administration** of currently approved on-demand medications[4-8] leads to treatment of a number of HAE attacks being **delayed or forgone**[9-13]
- An unmet need exists for **on-demand oral** therapies that are effective and well tolerated and may reduce the treatment burden thus enabling prompt administration[13]

cHMWK, cleaved HMWK; HMWK, high-molecular-weight kininogen. **1**. Betschel S, et al. *Allergy Asthma Clin Immunol.* 2019;15:72. **2**. Busse PJ, et al. *J Allergy Clin Immunol Pract.* 2021;9:132-50. **3**. Maurer M. et al. *Allergy.* 2022;77:1961-90. **4**. Berinert®. Package insert. Accessed September 19, 2024. https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf; **5**. Cinryze®. Summary of product characteristics. Accessed September 19. https://www.ema.europa.eu/en/documents/product-information/cinryze-epar-product-information_en.pdf; **6**. Firazyr®. Package insert. Accessed September 19, 2024. https://www.shirecontent.com/PI/PDFs/Firazyr_USA_ENG.pdf; **7**. Kalbitor®. Package insert. Accessed September 19, 2024. https://www.shirecontent.com/PI/PDFs/Kalbitor_USA_ENG.pdf; **8**. Ruconest®. Package insert. Accessed September 19, 2024. https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf; **9**. Burnette A, et al. Presented at: AAAAI; February 24–27, 2023; San Antonio, TX, USA. **10**. Tuong LA, et al. *Allergy Asthma Proc* 2014;35:250-4. **11.** Center for Biologics Evaluation and Research. The voice of the patient–Hereditary angioedema. US Food and Drug Administration. Accessed September 19, 2024. https://www.fda.gov/media/113509/download; **12**. Radojicic C, et al. Presented at: AAAAI; February 24–27, 2023; San Antonio, TX, USA. **13**. Mendevil J, et al. Presented at: ACAAI; November 9–13, 2023; Anaheim, CA, USA.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

RAPIDe-2 objectives and study design

- RAPIDe-2[1] is an ongoing, two-part, Phase 2/3 extension study evaluating long-term safety and efficacy of orally administered deucrictibant IR capsule for the treatment of HAE attacks.
  - Part A enrolls adult (≥18 years) participants who completed RAPIDe-1.
  - In Part A, participants continue self-administering the same double-blinded dose of deucrictibant IR capsule (10 mg, 20 mg, or 30 mg) received in RAPIDe-1 to treat qualifying non-laryngeal attacks (≥1 symptom with Visual Analogue Scale score ≥30), and laryngeal attacks presenting without breathing difficulties.
  - This presentation reports the data from the RAPIDe-2 Part A combined-dose group at the date of cutoff.



HAE, hereditary angioedema; IR, immediate-release. 1. RAPIDe-2. ClinicalTrial.org identifier NCT05396105. Accessed September 19, 2024. https://clinicaltrials.gov/study/NCT05396105

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Study endpoints

- **Primary endpoint:** Safety, including TEAEs, clinical laboratory tests, vital signs, and ECG findings.
- **Efficacy:** Assessed using PRO tools.
- **Key efficacy endpoints**:
  - **Time to onset of symptom relief**: PGI-C rating of at least "a little better" for 2 consecutive timepoints by 12 hours post-treatment.
  - **Time to reduction in attack severity**: ≥1-level reduction in PGI-S from pre-treatment for 2 consecutive timepoints by 12 hours post-treatment.
  - **Proportion of attacks achieving complete attack resolution**: PGI-S rating of "none" at 24 hours post-treatment.

Patient Global Impression of Change[1]



Patient Global Impression of Severity[1]

ECG, electrocardiogram; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity; PRO, patient-reported outcome; TEAE, treatment-emergent adverse event. **1.** Cohn DM, et al. *Clin Transl Allergy*. 2023;e12288.

Baseline characteristics

- 265 attacks from 17 participants included in the mITT efficacy analysis set (data cutoff: 01 March 2024).[a]
- 337 attacks from 19 participants included in the safety analysis set (data cutoff: 10 June 2024).[b]
  - 7 of 337 attacks were laryngeal.
- Baseline characteristics consistent with the RAPIDe-1 Phase 2 trial.

	Deucrictibant IR capsule (combined dose group)
Number of attacks treated[c]	337
Number of participants[c]	19
Age in years, mean (SD)	42.7 (17.6)
Sex: Male/female, n (%)	7 (36.8) / 12 (63.2)
Race: White/other	18 / 1
BMI, mean (SD)	27.0 (3.8)
Years since HAE diagnosis, mean (SD)	21.7 (15.2)
HAE type, n (%)	
HAE-1	17 (89.5)
HAE-2	2 (10.5)

BMI, body mass index; HAE, hereditary angioedema; IR, immediate-release; mITT, modified intention-to-treat; PGI-C, Patient Global Impression of Change; SD, standard deviation. [a]All participants who had ≥1 attack treated with deucrictibant and non-missing PGI-C results from ≥1 post-treatment timepoint. [b]All participants who received any dose of deucrictibant in the study. [c]Number by the cutoff date of 10 June 2024.

Deucrictibant was well tolerated across all doses

- No treatment-related TEAEs.
- No treatment-related serious or severe TEAEs, no treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings.
- No TEAEs leading to treatment discontinuation, study withdrawal, or death.

TEAEs within 5 days after administration of study drug

Adverse events	Deucrictibant IR capsule (combined dose group)
Number of attacks treated[a]	337
Number of participants[a]	19
Attacks with any TEAE, n (%)	13 (3.9)
Treatment-related TEAEs, n	0
Serious TEAEs, n	1[b]
Treatment-related serious TEAEs, n	0
TEAEs leading to study drug discontinuation, study withdrawal, or death, n	0

ECG, electrocardiogram; IR, immediate-release; TEAE, treatment-emergent adverse event (defined as adverse event occurring during time window from first study drug administration). [a]Number in the safety analysis set (data cutoff: 10 June 2024). [b]Tooth caries unrelated to treatment.

1.1 hours median time to onset of symptom relief using PGI-C



1.1 hours (95% CI, 1.0, 1.2)
median time to onset of symptom relief using PGI-C[b]



98.5%
(261/265) of attacks achieved onset of symptom relief using PGI-C[b] by 12 hours

IR, immediate-release; PGI-C, Patient Global Impression of Change. [a]Includes 10 mg, 20 mg, and 30 mg dose groups. [b]PGI-C rating of at least "a little better" for 2 consecutive timepoints by 12 hours post-treatment.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

97.7% of attacks achieved reduction in attack severity using PGI-S by 12 hours

2.6 hours (95% CI, 2.0, 2.9)
median time to reduction in attack severity using PGI-S[a]



97.7%
(255/261[b]) of attacks achieved reduction in attack severity using PGI-S[a] by 12 hours

PGI-S, Patient Global Impression of Severity. [a]≥1 point reduction in PGI-S from pre-treatment for 2 consecutive timepoints by 12 hours post-treatment. [b]261 attacks have non-missing pre-treatment PGI-S.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

85.8% of attacks achieved complete attack resolution by 24 hours with a median time of 11.5 hours

11.5 hours (95% CI, 11.0, 13.0)
median time to complete attack resolution using PGI-S[a]

90.2% (202/224) of attacks achieved this milestone with a single dose of deucrictibant IR capsule.



85.8%
(224/261[b]) of attacks achieved complete attack resolution using PGI-S[a] by 24 hours

Attacks treated with 1 or 2 doses of deucrictibant prior to achieving complete attack resolution



CI, confidence interval; IR, immediate-release; PGI-S, Patient Global Impression of Severity. [a]PGI-S rating of "none" at 24 hours post-treatment. [b]261 attacks have non-missing pre-treatment PGI-S. [c]Percentage of 224 attacks achieving complete attack resolution using PGI-S by 24 hours.

Overall, 86.0% of attacks were treated with a single dose of deucrictibant

Attacks treated with 1 or 2 doses of deucrictibant



IR, immediate-release.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Conclusions

- In the current analysis of the ongoing RAPIDe-2 Phase 2/3 extension study, deucrictibant IR capsule was well tolerated for all studied doses with no safety signals observed.
- Efficacy analysis showed:
  - 1.1 hours median time to onset of symptom relief using PGI-C – 98.5% of attacks by 12 hours.
  - 2.6 hours median time to reduction in attack severity using PGI-S – 97.7% of attacks by 12 hours.
  - 11.5 hours median time to complete attack resolution using PGI-S – 85.8% of attacks by 24 hours.
  - 86.0% of attacks were treated with a single dose of deucrictibant IR capsule.
- Results from the ongoing RAPIDe-2 extension are consistent with the Phase 2 RAPIDe-1 study and provide evidence on the long-term safety and efficacy of deucrictibant IR capsule for repeat treatment of HAE attacks.

The Authors and the Sponsor would like to thank all the people with HAE as well as all study site staff who participated in the RAPIDe-2 trial.

HAE, hereditary angioedema; IR, immediate-release; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity.